NANOVI A/S - CVR: 34889031

2022, DKK

19.12.2023

Bruttoresultat

464'

Primær drift

-22.091'

Årets resultat

-20.220'

Aktiver

12.504'

Kortfristede aktiver

12.188'

Egenkapital

-18.059'

Afkastningsgrad

-177 %

Soliditetsgrad

-144 %

Likviditetsgrad

436 %

Resultat

19.12.2023

Årsrapport	2022 19.12.2023	2021 31.05.2022	2020 31.05.2021	2019 31.08.2020	2018 31.05.2019	2017 01.06.2018	2016 01.06.2017	2015 11.04.2016
Nettoomsætning	736.815	687.753	111.120	394.489	195.585
Bruttoresultat	464.012	419.445	66.644	174.263	176.523			0
Resultat af primær drift	-22.090.583	-17.235.552	-12.050.702	-11.886.253	-8.354.849	-10.083.359	-6.568.460	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0			0
Finansielle indtægter	20.431	81.421	7.167	18.858	5.928	1.895	4.874	1.048
Finansieringsomkostninger	-2.065.772	-1.614.813	-761.944	-1.683.133	-1.814.195	-1.701.096	-1.101.363	-436.862
Andre finansielle omkostninger	0	0	0	0	0			0
Resultat før skat	-24.135.924	-18.768.944	-12.805.479	-13.550.528	-10.163.116	-11.782.560	-7.664.949	-8.154.873
Resultat	-20.220.421	-16.021.778	-11.115.202	-11.708.528	-9.046.741	-10.374.041	-6.426.868	-7.169.287
Forslag til udbytte	0	0	0	0	0			0

Aktiver

19.12.2023

Årsrapport	2022 19.12.2023	2021 31.05.2022	2020 31.05.2021	2019 31.08.2020	2018 31.05.2019	2017 01.06.2018	2016 01.06.2017	2015 11.04.2016
Kortfristede varebeholdninger	345.986	1.154.410	1.483.523	681.052	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	4.835.671	4.164.121	3.448.392	3.087.735	1.909.482	0	0	1.702.493
Likvider	7.006.642	27.065.780	42.838.896	17.860.352	8.698.606	1.699.629	3.649.933	1.040.525
Kortfristede aktiver	12.188.299	32.384.311	47.770.811	21.629.139	10.608.088	3.927.900	5.117.254	2.743.018
Immaterielle aktiver og goodwill	0	0	0	0	0	0	0	0
Finansielle anlægsaktiver	87.666	117.730	85.526	85.526	79.603			30.739
Materielle aktiver	228.289	457.732	601.192	806.907	960.407	0	0	0
Langfristede aktiver	315.955	575.462	686.718	892.433	1.040.010	37.095	30.820	30.739
Aktiver	12.504.254	32.959.773	48.457.529	22.521.572	11.648.098	3.964.995	5.148.074	2.773.757

Aktiver

19.12.2023

Passiver

19.12.2023

Årsrapport	2022 19.12.2023	2021 31.05.2022	2020 31.05.2021	2019 31.08.2020	2018 31.05.2019	2017 01.06.2018	2016 01.06.2017	2015 11.04.2016
Forslag til udbytte	0	0	0	0	0			0
Egenkapital	-18.058.756	2.161.665	18.183.443	12.963.292	-7.067.171	-13.790.592	-8.420.166	-3.624.312
Hensatte forpligtelser	0	0	0	0	0			0
Langfristet gæld til banker	0	0	0	0	0			0
Anden langfristet gæld	721.872	721.872	711.204	223.294	0			0
Langfristede forpligtelser						16.590.590	12.910.542
Kortfristede forpligtelser						1.164.996	657.698
Leverandører af varer og tjenesteydelser	1.119.553	742.308	955.965	1.171.640	1.066.173			1.577.104
Kortfristede forpligtelser	2.797.795	3.135.731	2.300.969	2.306.522	1.721.179			1.955.681
Gældsforpligtelser	30.563.010	30.798.108	30.274.086	9.558.280	18.715.269			6.398.069
Forpligtelser	30.563.010	30.798.108	30.274.086	9.558.280	18.715.269	17.755.586	13.568.240	6.398.069
Passiver	12.504.254	32.959.773	48.457.529	22.521.572	11.648.098	3.964.995	5.148.074	2.773.757

Passiver

19.12.2023

Nøgletal

19.12.2023

Årsrapport	2022 19.12.2023	2021 31.05.2022	2020 31.05.2021	2019 31.08.2020	2018 31.05.2019	2017 01.06.2018	2016 01.06.2017	2015 11.04.2016
Afkastningsgrad	-176,7 %	-52,3 %	-24,9 %	-52,8 %	-71,7 %	-254,3 %	-127,6 %	Na.
Dækningsgrad	63,0 %	61,0 %	60,0 %	44,2 %	90,3 %			Na.
Resultatgrad	-2.744,3 %	-2.329,6 %	-10.002,9 %	-2.968,0 %	-4.625,5 %	Na.	Na.	Na.
Varelagerets omsætningshastighed	2,1	0,6	0,1	0,6	Na.	Na.	Na.	Na.
Egenkapitals-forretning	112,0 %	-741,2 %	-61,1 %	-90,3 %	128,0 %	75,2 %	76,3 %	197,8 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.			Na.
Gældsdæknings-nøgletal	-1.069,4 %	-1.067,3 %	-1.581,6 %	-706,2 %	-460,5 %	-592,8 %	-596,4 %	Na.
Soliditestgrad	-144,4 %	6,6 %	37,5 %	57,6 %	-60,7 %	-347,8 %	-163,6 %	-130,7 %
Likviditetsgrad	435,6 %	1.032,8 %	2.076,1 %	937,7 %	616,3 %			140,3 %

Resultat

19.12.2023

Gæld

19.12.2023

Årsrapport

19.12.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 19.12.2023)

Information om virksomhedens regnskabsklasse:The annual report of Nanovi A/S for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

19.12.2023

Dato for ledelsens godkendelse af årsrapporten:2023-12-01

Oplysning om usædvanlige forhold:Financing and the going concern assumption Following the completion of the reconstruction, as discussed in section note 3 - Events after the balance sheet date, the company’s shareholders’ equity on 30 September 2023 amounted to DKK 400,000 and total assets amounted to DKK 400,000, of which DKK 0 was cash. Nanovi has obtained a letter of financial support from its owner, Sinmed Holding International B. V., according to which Sinmed Holding International B. V. guarantees that it will support Nanovi financially at least through December 31, 2023. In the view of management and the board of directors, the letter of financial support provides the company with access to a satisfactory funding assurance to continue its operations and settle all operational payables as they fall due for payment at least through December 31, 2023. On this basis, the Company has presented its financial statements for 2022 on a going concern assumption.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Nanovi A/S for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Nanovi is a medical device company focused on the development and commercialization of liquid soft tissue markers with radiographic visibility to open new therapeutic opportunities in the field of high precision radiation and surgery. It is our mission to empower healthcare providers to deliver optimal outcomes in cancer therapy for the benefit of patients and for higher efficiency in healthcare. BioXmark® is our first liquid soft tissue marker for human use. This marker is intended to enhance target visibility on medical imaging for better guidance of high precision radiation therapy across multiple cancer types. BioXmark® was CE marked in 2020 and has since then been commercially available across all EU member countries. In late 2022, BioXmark® was approved for the US market with an FDA clearance under the De Novo pathway. PetXmark™ is a veterinary version of BioXmark®, which has been commercially available in the US since 2019 to mark soft tissue in cats and dogs and guide high precision radiation therapy for pets with cancer. Business activities during 2022 In the reporting year, Nanovi continued to expand the awareness of BioXmark® and build customer relations among cancer radiation clinics in Europe. In parallel, substantial additional clinical safety and feasibility evidence was established for the product from Investigator Initiated Trials and post-marketing user studies across several cancer indications. In March 2022, a De Novo application was submitted to the FDA requesting marketing approval for BioXmark® in the U. S. The submitted file was accepted for regulatory review in April and in late December, the product was cleared for the U. S market as a class II medical device. In parallel, the company significantly advanced the project to transfer and upscale the manufacturing process for BioXmark® with a new MDR and FDA compliant contract manufacturer, EMCM in the Netherlands. In the first half of the year, also the research and development of a new liquid surgical marker was accelerated. During spring 2022, the shareholders initiated a process to sell the company to a commercially strong player with the necessary capacity to effectively scale sales of BioXmark® in Europe and introduce the product on the U. S. market. Dialogues were initiated with interested buyers, however due to the geopolitical and economic unrest during Summer, no bids were received. This led to a decision in Q3 2022 to significantly downscale operations to safeguard cash reserves and ensure liquidity to meet the goals of FDA clearance of BioXmark® and transfer to an FDA compliant manufacturer to get products ready for the U. S. market.